AstraZeneca Strengthens its Position in China with Guangdong BeiKang Pharmaceutical Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 12 (Table of Contents)
Published: 22 Dec-2011
DOI: 10.3833/pdr.v2011.i12.1641 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
AstraZeneca, the second biggest foreign pharmaceutical company in China after Pfizer, has strengthened its position in this market by acquiring Guangdong BeiKang Pharmaceutical, a manufacturer of generic injectable antibiotics, for an undisclosed sum...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS